VistaGen Therapeutics Stock
VistaGen Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Shawn K. Singh
- Employees
- 41
- Market cap
- $9 M
- IPO
- 21/06/2011
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray…
VistaGen Therapeutics stock: price history
1D
-6.1%
1W
-15.3%
1M
-13.3%
6M
-68.1%
YTD
-69.8%
1Y
-95.1%
2Y
-93.4%
5Y
-99.7%
10Y
-99.8%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~94% stronger price swings than usual
Ask the agents about VistaGen Therapeutics
Analyst assessment of VistaGen Therapeutics
PRICE TARGET LOW
US$0.90
CONSENSUS
US$0.95
MEDIAN
US$0.95
PRICE TARGET HIGH
US$1.00
0
STRONG BUY
3
BUY
4
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Hold
As of: 17/12/2025
VistaGen Therapeutics stock metrics
P/E
-0.12
P/B
0.35
EV/EBITDA
0.11
RETURN ON EQUITY
-53.2%
NET MARGIN
-882.8%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.0%
FLOAT SHARES
35,066,745
AVG. DAILY VOLUME (30D)
21,172,036
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about VistaGen Therapeutics stock
What does VistaGen Therapeutics do?
VistaGen Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Shawn K. Singh, the company employs around 41 people.
The IPO was on 21/06/2011; the stock trades on NASDAQ under the ticker VTGN.
What do analysts say about VistaGen Therapeutics stock?
7 analysts rate the stock, the consensus is Hold (as of 17/12/2025).
The average price target is US$0.95, ranging from US$0.90 to US$1.00, with a median of US$0.95.
This is an external assessment, not a statement by Market Jury.
When does VistaGen Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 94% stronger than usual.
Does VistaGen Therapeutics pay a dividend?
No, VistaGen Therapeutics currently does not pay a dividend.
Which stocks are comparable to VistaGen Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get VistaGen Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess VistaGen Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.